Fujifilm to seek approval for COVID-19 drug Avigan possibly in Oct.

Fujifilm Holdings Corp. said Wednesday it will seek regulatory approval as early as October for using its antivirus drug Avigan to treat patients infected with the novel coronavirus as clinical tests have shown efficacy in easing symptoms.According to analysis of data on 156 patients without severe symptoms, Fujifilm found those administered with Avigan show improvement after 11.9 days, shorter than the 14.7 days for those in a placebo group.If approved, the drug, also known as favipiravir, would be the third treatment drug for COVID-19, the respiratory disease caused by the virus.Fujifilm …READ FULL ARTICLE